Reactive Oxygen Species (ROS) in Metabolic Disease—Don’t Shoot the Metabolic Messenger
International Journal of Molecular Sciences · 14.03.2025 · 26 (6) · 2622
DOI: 10.3390/ijms26062622 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 14.03.2025. Verfasst von Ross T Lindsay und 1 weiteren Autor:innen. Beteiligte Einrichtung: Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA. Hauptthemen laut MEDLINE: Reactive Oxygen Species, Metabolic Diseases. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 227 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Reactive oxygen species (ROS) are widely considered key to pathogenesis in chronic metabolic disease. Consequently, much attention is rightly focused on minimising oxidative damage. However, for ROS production to be most effectively modulated, it is crucial to first appreciate that ROS do not solely function as pathological mediators. There are >90 gene products specifically evolved to generate, handle, and tightly buffer the cellular concentration of ROS. Therefore, it is likely that ROS plays a role as integral homeostatic signalling components and only become toxic in extremis. This review explores these commonly overlooked normal physiological functions, including how ROS are generated in response to environmental or hormonal stimuli, the mechanisms by which the signals are propagated and regulated, and how the cell effectively brings the signal to an end after an appropriate duration. In the course of this, several specific and better-characterised signalling mechanisms that rely upon ROS are explored, and the threshold at which ROS cross from beneficial signalling molecules to pathology mediators is discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA.
- Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, UK.
Zitieren
APA
Lindsay, R. T., & Rhodes, C. J. (2025). Reactive Oxygen Species (ROS) in Metabolic Disease—Don’t Shoot the Metabolic Messenger. International Journal of Molecular Sciences, 26(6), 2622. https://doi.org/10.3390/ijms26062622
Vancouver
Lindsay RT, Rhodes CJ. Reactive Oxygen Species (ROS) in Metabolic Disease—Don’t Shoot the Metabolic Messenger. International Journal of Molecular Sciences. 2025;26(6):2622. doi:10.3390/ijms26062622
BibTeX
@article{Lindsay2025,
author = {Lindsay, Ross T and Rhodes, Christopher J},
title = {Reactive Oxygen Species (ROS) in Metabolic Disease—Don’t Shoot the Metabolic Messenger},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {6},
pages = {2622},
doi = {10.3390/ijms26062622}
}
EUVIMED